19178-11-1

Basic information

• Product Name: 7,8-dimethoxyquinazolin-4(3H)-one
• Synonyms: 7,8-dimethoxyquinazolin-4(3H)-one;4(3H)-Quinazolinone, 7,8-dimethoxy-;7,8-Dimethoxy-3H-quinazolin-4-one;7,8-diMethoxy-3,4-dihydroquinazolin-4-one;7,8-dimethoxy-4(3H)-Quinazolinone
• CAS NO: 19178-11-1
• Molecular Formula: C₁₀H₁₀N₂O₃
• Molecular Weight: 206
• EINECS: 604-604-1
• Mol File: 19178-11-1.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 7,8-dimethoxyquinazolin-4(3H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 7,8-dimethoxyquinazolin-4(3H)-one(19178-11-1)
• EPA Substance Registry System: 7,8-dimethoxyquinazolin-4(3H)-one(19178-11-1)

Safety Data

• Hazardous Substances Data: 19178-11-1(Hazardous Substances Data)

Usage

General Description

7,8-dimethoxyquinazolin-4(3H)-one, also known as DMQ, is a chemical compound with a quinazolinone structure. It is a white solid with the molecular formula C11H10N2O3 and a molecular weight of 214.21 g/mol. DMQ has been studied for its potential therapeutic applications, particularly in the field of medicinal chemistry. It has been investigated for its anti-inflammatory, antitumor, and antiviral properties, as well as for its potential use in the treatment of various diseases and conditions. Additionally, DMQ has been examined for its potential use as a building block in the synthesis of other biologically active compounds. Overall, 7,8-dimethoxyquinazolin-4(3H)-one is a versatile chemical with potential applications in various fields of science and medicine.

Upstream product

• 5701-87-1 3,4-dimethoxyanthranilic acid 
• 149-73-5 trimethyl orthoformate 
• 79025-28-8 3,4-Dimethoxy-2-nitro-benzoic acid 
• 55149-84-3 2-nitroveratraldehyde 

Relevant articles and documents

Small-molecule phosphodiesterase probes: Discovery of potent and selective CNS-penetrable quinazoline inhibitors of PDE1

PDE1 is a family of calcium-activated, dual substrate phosphodiesterases expressed in both the CNS and periphery that play a role in the integration of intracellular calcium and cyclic nucleotide signaling cascades. Exploration of the potential in targeting this family of enzymes to treat neuropsychiatric disorders has been hampered by a lack of potent, selective, and brain penetrable PDE1 inhibitors. To identify such compounds we used high-throughput screening, structure-based design, and targeted synthetic chemistry to discover the 4-aminoquinazoline 7a (PF-04471141) and the 4-indanylquinazoline 27 (PF-04822163) each of which are PDE1 inhibitors that readily cross the blood brain barrier. These quinazoline-based PDE1-selective inhibitors represent valuable new tools to study the biological processes regulated by PDE1 and to begin to determine the potential therapeutic utility of such compounds to treat neuropsychiatric disorders.